
Opinion|Videos|September 18, 2024
Evaluating Imaging Agents in Oligometastatic Prostate Cancer: A Comparative Analysis of Gallium-Based and Non-Gallium-Based Options
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Medical experts conduct a comparative assessment of gallium-based and non-gallium-based imaging agents to determine their efficacy in detecting and characterizing oligometastatic prostate cancer.
Advertisement
Video content above is prompted by the following:
- Can you discuss the advantages and limitations of different imaging agents commonly used in identifying oligometastatic disease in prostate cancer, such as gallium-based agents versus non-gallium-based agents?
- Are you aware of any differences in lesion detection rates or staging accuracy between gallium vs non- gallium-based PET imaging agents?
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears New PET/MRI System from Siemens Healthineers
2
Large Mammography Study Suggests Adjunctive AI May Have an Impact in Reducing Interval Breast Cancer Rates
3
FDA Clears AI Software for PSMA PET/CT and SPECT/CT Tumor Burden Analysis
4
5T Prostate MRI Study Reveals Enhanced Image Quality and Detection
5











